Metronomic Capecitabine in Stage III Gastric Cancer

This study is testing whether adding low-dose, continuous oral chemotherapy (metronomic capecitabine) after surgery helps prevent recurrence in patients with stage III gastric (stomach) cancer who have already completed standard surgery and treatment. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with primary stage III stomach cancer confirmed by pathology - You have had successful complete (R0) surgery with removal of surrounding lymph nodes - Your general health is good (ECOG 0 or 1) and you are expected to live more than 6 months - Your blood counts, liver, kidney function, and heart test (ECG) are within normal ranges **You may NOT be eligible if...** - You have previously received chemotherapy, radiation, immunotherapy, or targeted therapy - You have multiple primary cancers - You have serious heart, lung, kidney, or liver disease - You have poorly controlled diabetes or other chronic conditions Talk to your doctor to see if this trial is right for you.